12/2/2025 | 22:28 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
12/2/2025 | 22:13 | EDGAR2 | Form 8-K - Current report |
12/2/2025 | 22:05 | GLOBE | Rezolute Reports Second Quarter Fiscal 2025 Financial.. |
04/2/2025 | 23:11 | EDGAR2 | Form 8-K - Current report |
04/2/2025 | 14:00 | GLOBE | Rezolute Provides Update on its Phase 3 sunRIZE Study of.. |
31/1/2025 | 14:00 | GLOBE | Rezolute to Participate in the Guggenheim SMID Cap Biotech.. |
14/1/2025 | 22:30 | EDGAR2 | Form 8-K - Current report |
07/1/2025 | 14:00 | GLOBE | Rezolute Receives Breakthrough Therapy Designation from FDA.. |
30/12/2024 | 22:05 | EDGAR2 | Form S-8 - Securities to be offered to employees in employee.. |
10/12/2024 | 22:43 | EDGAR2 | Form 8-K - Current report |
05/12/2024 | 14:00 | GLOBE | Rezolute Reports Inducement Award Under Nasdaq Listing Rule.. |
03/12/2024 | 14:00 | GLOBE | FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug.. |
15/11/2024 | 00:59 | EDGAR2 | Form SC 13G/A - Statement of Beneficial Ownership by Certain.. |
12/11/2024 | 15:35 | EDGAR2 | Form SC 13G/A - Statement of Beneficial Ownership by Certain.. |
07/11/2024 | 22:47 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
07/11/2024 | 22:38 | EDGAR2 | Form 8-K - Current report |
07/11/2024 | 22:05 | GLOBE | Rezolute Reports First Quarter Fiscal 2025 Financial Results.. |
05/11/2024 | 14:00 | GLOBE | Rezolute to Participate in Upcoming Investor Conferences |
21/10/2024 | 22:43 | EDGAR2 | Form DEFA14A - Additional definitive proxy soliciting.. |
21/10/2024 | 22:41 | EDGAR2 | Form DEF 14A - Other definitive proxy statements |
10/10/2024 | 22:40 | EDGAR2 | Form PRE 14A - Other preliminary proxy statements |
24/9/2024 | 23:14 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
19/9/2024 | 22:23 | EDGAR2 | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
19/9/2024 | 22:09 | EDGAR2 | Form 8-K - Current report |
19/9/2024 | 22:05 | GLOBE | Rezolute Reports Fourth Quarter and Full Year Fiscal 2024.. |
09/9/2024 | 13:30 | EDGAR2 | Form 8-K - Current report |
09/9/2024 | 13:30 | GLOBE | FDA Lifts Partial Clinical Holds on RZ358 for the Treatment.. |
27/8/2024 | 14:00 | GLOBE | Rezolute to Participate in Upcoming Investor Conferences |
15/8/2024 | 06:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
10/8/2024 | 03:47 | EDGAR2 | Form S-3/A - Registration statement under Securities Act of.. |
05/8/2024 | 23:00 | EDGAR2 | Form S-3 - Registration statement under Securities Act of.. |
05/8/2024 | 13:30 | EDGAR2 | Form 8-K - Current report |
05/8/2024 | 13:30 | GLOBE | Rezolute Announces FDA Clearance of IND Application for.. |
31/7/2024 | 14:00 | GLOBE | Rezolute to Participate in the BTIG Virtual Biotechnology.. |
27/6/2024 | 14:00 | GLOBE | Rezolute Announces Exercise of Underwriters’ Option to.. |
24/6/2024 | 14:00 | GLOBE | Rezolute Announces Closing of Public Offering with.. |
14/6/2024 | 22:51 | EDGAR2 | Form 8-K - Current report |
14/6/2024 | 22:49 | EDGAR2 | Form 424B5 - Prospectus [Rule 424(b)(5)] |
14/6/2024 | 18:51 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
14/6/2024 | 05:30 | GLOBE | Rezolute Announces Pricing of Public Offering of $60 Million.. |
13/6/2024 | 23:25 | EDGAR2 | Form 424B5 - Prospectus [Rule 424(b)(5)] |
13/6/2024 | 22:01 | GLOBE | Rezolute Announces Proposed Public Offering of Common Stock.. |
30/5/2024 | 14:00 | GLOBE | Rezolute to Participate in the Jefferies Global Healthcare.. |
28/5/2024 | 20:56 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
24/5/2024 | 20:37 | EDGAR2 | Form 8-K - Current report |
21/5/2024 | 22:05 | GLOBE | Rezolute Reports Positive Topline Results from Phase 2 Proof.. |
17/5/2024 | 22:21 | EDGAR2 | Form 8-K - Current report |
15/5/2024 | 22:25 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
15/5/2024 | 22:05 | GLOBE | Rezolute Reports Third Quarter Fiscal 2024 Financial Results.. |
23/4/2024 | 14:00 | GLOBE | Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024.. |